LETTER TO THE EDITOR
Role of myoinositol hexaphosphate (SNF 472) in calciphylaxis: an update
Atif Ibrahim,
Corresponding Author
Atif Ibrahim
The University of Tennessee Health Science Center, Memphis, Tennessee, USA
Correspondence
Atif Ibrahim, Fellow - Internal Medicine/Nephrology, The University of Tennessee Health Science Center, Department of Nephrology, Suite H314 956 Court Ave Memphis, TN 38163.
Email: [email protected]
Search for more papers by this author Mohammad Ebad Ur Rehman,
Mohammad Ebad Ur Rehman
Rawalpindi Medical University, Rawalpindi, Pakistan
Search for more papers by this author Muhammad Zubair Khan,
Muhammad Zubair Khan
Ayub Medical College, Abbottabad, Pakistan
Search for more papers by this author
Atif Ibrahim,
Corresponding Author
Atif Ibrahim
The University of Tennessee Health Science Center, Memphis, Tennessee, USA
Correspondence
Atif Ibrahim, Fellow - Internal Medicine/Nephrology, The University of Tennessee Health Science Center, Department of Nephrology, Suite H314 956 Court Ave Memphis, TN 38163.
Email: [email protected]
Search for more papers by this author Mohammad Ebad Ur Rehman,
Mohammad Ebad Ur Rehman
Rawalpindi Medical University, Rawalpindi, Pakistan
Search for more papers by this author Muhammad Zubair Khan,
Muhammad Zubair Khan
Ayub Medical College, Abbottabad, Pakistan
Search for more papers by this author
First published: 22 February 2022
No abstract is available for this article.
REFERENCES
- 1Perello J, Joubert PH, Ferrer MD, Canals AZ, Sinha S, Salcedo C. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. Br J Clin Pharmacol. 2018; 84(12): 2867–76.
- 2Perello J, Gomez M, Ferrer MD, Rodriguez NY, Salcedo C, Buades JM, et al. SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. J Nephrol. 2018; 31(2): 287–96.
- 3Brandenburg VM, Sinha S, Torregrosa JV, Garg R, Miller S, Canals AZ, et al. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. J Nephrol. 2019; 32(5): 811–21.
- 4Sinha S, Gould LJ, Nigwekar SU, Serena TE, Brandenburg V, Moe SM, et al. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clin Kidney J. 2022; 15(1): 136–44.
